The Gastrointestinal Manifestations in Patients with COVID-19 and their Clinical Correlates in An Adult Iraqi Population Sample

Rabah Hiab Asreah; Akram Rasool  Kadhim; Abdul Wahab Abdul  Hameed

doi:10.51699/cajmns.v6i4.2979

Authors

Rabah Hiab Asreah Iraqi Ministry of Health, Baghdad Medical City, Baghdad Teaching Hospital, Baghdad, Iraq
Akram Rasool Kadhim Iraqi Ministry of Health, Thi Qar Health Directorate, Al-Shatra General Hospital, Thi-Qar, Iraq
Abdul Wahab Abdul Hameed Iraqi Ministry of Health, Baghdad Medical City, Baghdad Teaching Hospital, Baghdad, Iraq

DOI:

https://doi.org/10.51699/cajmns.v6i4.2979

Keywords:

Gastrointestinal, COVID-19,, Inflammation

Abstract

The gastrointestinal system is one of the many organs in the body that have been affected by the new viral illness known as coronavirus disease 2019 (COVID-19). To find out the GIT symptoms are into patients with Covid-19 and how they correspond with the severity of the illness. At the Al-Shifaa facility, 172 patients infected with COVID-19 participated in our study. A clinical examination, laboratory tests (CRP, D.Dimer, and serum ferritin), a chest CT scan, and a medical history were performed on each patient. The severity of the illness and other factors were taken into consideration while evaluating the gastrointestinal symptoms. Data collection from 172 patients, 91 patients infected with COVID-19 infection, 91 patients (52.9%) had GIT manifestation, while 81 patients (47.1%) had without GIT manifestation. According to the severity 117 patients had severe infection of them 60 patients (51.3%) had GIT manifestation and 57 patients (48.7%) without GIT manifestation; 31 patients had moderate infection 20 patients (64.5%) of them had GIT manifestation, and 11 patients (35.5%) without, 24 patients had mild infection 11 patients (45.8%) had GIT manifestation, and 13 patients( 54.2%) without. According to gender, 82 patients( 47.7%) were female (50 patients (61.0%) had GIT manifestation and 32 patients (39.9%) without), 90 patients (52.3%) were male (41 patients (45.65%) had GIT manifestation and 49 patients (54.4%) without). By comparison of inflammatory markers (in the form of CRP titer, D.Dimer, and sr. ferritin ) which were 99.21 ± 13.71, 2.13 ±0.28, and 642.66±49.95 respectively, in those with SARS-CoV-2 infection and 83.37±8.69, 2.19±0.34 and 606±58.57, respectively, for those with no GIT symptoms (p-value =0.34, 0.89, and 0.62, respectively). GIT manifestations are common symptoms in patients with COVID-19. The incidence of GIT manifestations is not affected by the disease severity in SARS-CoV-2 infection. Inflammatory markers (in the form of CRP titer, ferritin, and D-dimer) are not related to the incidence of GIT manifestations in COVID–19 infection.

References

N. Aumpan, P. Nunanan, and R.K. Vilaichone, "Gastrointestinal manifestation as a clinical predictor of severe COVID-19: A retrospective experience and literature review of COVID-19 in the Association of Southeast Asian Nations (ASEAN)," JGH Open, vol. 4, no. 6, pp. 1096-1101, Dec. 2020.

W. Shang, J. Dong, Y. Ren, M. Tian, W. Li, et al., "The value of clinical parameters in predicting the severity of COVID‐19," J. Med. Virol., vol. 92, no. 10, pp. 2188-2192, Oct. 2020.

F. Khalaf, A.A. Ali Ismael, and A. Baghdadi, "Clinical diagnosis of the first cases of extrapulmonary (GIT) COVID-19 in Thi-Qar, south of Iraq," System. Rev. Pharm., vol. 11, no. 12, pp. 1712-1716, 2020.

U.C. Ghoshal, U. Ghoshal, A. Mathur, R.K. Singh, A. Nath, et al., "The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome," Clin. Transl. Gastroenterol., vol. 11, no. 12, Dec. 2020.

J. Samanta, J. Dhar, A. Khaliq, and R. Kochhar, "2019 novel coronavirus infection: gastrointestinal manifestations," J. Digestive Endosc., vol. 11, no. 1, pp. 13-18, Mar. 2020.

J.M. Remes-Troche, A. Ramos-de-la-Medina, M. Manríquez-Reyes, L. Martínez-Pérez-Maldonado, E.L. Lara, et al., "Initial gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus two infection in 112 patients from Veracruz in southeastern Mexico," Gastroenterology, vol. 159, no. 3, pp. 1179-1181, Sep. 2020.

F. D’amico, D.C. Baumgart, S. Danese, and L. Peyrin-Biroulet, "Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management," Clin. Gastroenterol. Hepatol., vol. 18, no. 8, pp. 1663-1672, Jul. 2020.

F. Trottein and H. Sokol, "Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection," Cell Reports, vol. 32, no. 3, p. 107915, Jul. 21, 2020.

Q. Ye, B. Wang, T. Zhang, J. Xu, and S. Shang, "The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19," Am. J. Physiol. Gastrointest. Liver Physiol., vol. 319, no. 2, pp. G245-G252, 2020.

B. Aktaş and B. Aslim, "Gut-lung axis and dysbiosis in COVID-19," Turk. J. Biol., vol. 44, SI-1, pp. 265-272, Jun. 21, 2020.

W.D. Redd, J.C. Zhou, E. Hathorn, et al., "Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: A multicenter cohort study," Gastroenterology, Apr. 22, 2020. [Online]. Available: https://doi.org/10.1053/j.gastro.2020.04.045.

Z. Yu, Z. Yang, Y. Wang, F. Zhou, S. Li, et al., "Recent advances of ACE2 and microbiota dysfunction in COVID-19 pathogenesis," Heliyon, vol. 7, no. 7, p. e07548, Jul. 2021.

K.F. Budden, S.L. Gellatly, D.L. Wood, M.A. Cooper, M. Morrison, et al., "Emerging pathogenic links between microbiota and the gut-lung axis," Nat. Rev. Microbiol., vol. 15, no. 1, pp. 55-63, Jan. 2017.

S. Villapol, "Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome," Transl. Res., vol. 226, pp. 57-69, Dec. 2020.

A.E. Livanos, D. Jha, F. Cossarini, A.S. Gonzalez-Reiche, M. Tokuyama, et al., "Gastrointestinal involvement attenuates COVID-19 severity and mortality," MedRxiv, Jan. 1, 2020.

S. Parasa, M. Desai, V.T. Chandrasekar, H.K. Patel, K.F. Kennedy, et al., "Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis," JAMA Netw. Open, vol. 3, no. 6, p. e2011335, Jun. 1, 2020.

A. Aghemo, D. Piovani, T.L. Parigi, E. Brunetta, N. Pugliese, et al., "COVID-19 digestive system involvement and clinical outcomes in a large academic hospital in Milan, Italy," Clin. Gastroenterol. Hepatol., vol. 18, no. 10, pp. 2366-2368, Sep. 1, 2020.

A.A.A. Teima, A.A. Amer, A. Mohammed, et al., "A cross-sectional study of gastrointestinal manifestations in COVID-19 Egyptian patients," Ann. Med. Surg., p. 103234, 2022.

L. Lin, X. Jiang, Z. Zhang, S. Huang, Z. Zhang, et al., "Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection," Gut, vol. 69, no. 6, pp. 997-1001, Jun. 1, 2020.

R. Mao, Y. Qiu, J.S. He, J.Y. Tan, X.H. Li, et al., "Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis," Lancet Gastroenterol. Hepatol., vol. 5, no. 7, pp. 667-678, Jul. 1, 2020.